At least modestly effective, phase III data show
Phase III results, now published, should support approval
These eight specialties earn the least, with many averaging less than $300k per year
Trial finds conservative approach inferior to joint replacement
Study: It's not deprivation per se, but intervening factors that go with it
Looks like FDA blew the call on selective JAK1 inhibitor
Treatment patterns shift as new products come on board
Taking a page from HIV medicine
European registry analysis brings surprises along with the expected
But Japanese study suggests losses need to be substantial
Carefully structured run-walk program proves mettle in small trial
While imperfect relative to human experts, system might still be clinically useful
Only limited value when costs are considered, study suggests
MRI does occasionally reveal important findings missed on x-ray